1. Xu, Min, Zheng, Jing, Wang, Jun, Hu, Gang, He, Hailan. 2023. MCF2L-AS1/miR-874-3p/STAT3 feedback loop contributes to lung adenocarcinoma cell growth and cisplatin resistance. In Heliyon, 9, e21342. doi:10.1016/j.heliyon.2023.e21342. https://pubmed.ncbi.nlm.nih.gov/37954302/
2. Ou, Hongliang, Qian, Yunsong, Ma, Li. 2023. MCF2L-AS1 promotes the biological behaviors of hepatocellular carcinoma cells by regulating the miR-33a-5p/FGF2 axis. In Aging, 15, 6100-6116. doi:10.18632/aging.204795. https://pubmed.ncbi.nlm.nih.gov/37432067/
3. Shepherd, Colin, Skelton, Andrew J, Rushton, Michael D, Reynard, Louise N, Loughlin, John. 2015. Expression analysis of the osteoarthritis genetic susceptibility locus mapping to an intron of the MCF2L gene and marked by the polymorphism rs11842874. In BMC medical genetics, 16, 108. doi:10.1186/s12881-015-0254-2. https://pubmed.ncbi.nlm.nih.gov/26584642/
4. Kong, Wencheng, Li, Hui, Xie, Lesi, Ma, Wencong, Zhou, Yifeng. 2021. LncRNA MCF2L-AS1 aggravates the malignant development of colorectal cancer via targeting miR-105-5p/RAB22A axis. In BMC cancer, 21, 1069. doi:10.1186/s12885-021-08668-w. https://pubmed.ncbi.nlm.nih.gov/34592939/
5. Mitchell, S E, Martin, R P, Terry, P, Dietz, H, Sobreira, N. 2023. Systemic artery to pulmonary artery aneurysm malformations associated with variants at MCF2L. In American journal of medical genetics. Part A, 191, 1250-1260. doi:10.1002/ajmg.a.63141. https://pubmed.ncbi.nlm.nih.gov/36760094/
6. Zhu, Yan, Yang, Lijuan, Wang, Jianqing, Li, Yan, Chen, Youguo. 2022. SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis. In Journal of gynecologic oncology, 33, e75. doi:10.3802/jgo.2022.33.e75. https://pubmed.ncbi.nlm.nih.gov/36245227/
7. Chen, Qiaofeng, Wang, Meiai, Wu, Shanpeng. 2020. The lncRNA MCF2L-AS1 controls osteogenic differentiation by regulating miR-33a. In Cell cycle (Georgetown, Tex.), 19, 1059-1065. doi:10.1080/15384101.2020.1747776. https://pubmed.ncbi.nlm.nih.gov/32255731/
智鼠故事 
